(R)-2-(5-(4-methoxyphenyl)-2-methylfuran-3-carboxamido)-3-(naphthalene-6-yl)propanoic acid | 1207726-05-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (R)-2-(5-(4-methoxyphenyl)-2-methylfuran-3-carboxamido)-3-(naphthalene-6-yl)propanoic acid
• 英文别名: (R)-2-(5-(4-methoxyphenyl)-2-methylfuran-3-carboxamido)-3-(naphthalen-2-yl)propanoic acid；(2R)-2-[[5-(4-methoxyphenyl)-2-methylfuran-3-carbonyl]amino]-3-naphthalen-2-ylpropanoic acid
• CAS: 1207726-05-3
• 化学式: C₂₆H₂₃NO₅
• 分子量: 429.472
• InChiKey: VXXTXOXICOOAFL-HSZRJFAPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  88.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  methyl (R)-2-(5-(4-methoxyphenyl)-2-methylfuran-3-carboxamido)-3-(naphthalen-2-yl)propanoate 在 水 、 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 以100%的产率得到(R)-2-(5-(4-methoxyphenyl)-2-methylfuran-3-carboxamido)-3-(naphthalene-6-yl)propanoic acid
  参考文献：
  名称：

  Structure-guided design of α-amino acid-derived Pin1 inhibitors

  摘要：

  The peptidyl prolyl cis/trans isomerase Pin1 is a promising molecular target for anti-cancer therapeutics. Here we report the structure-guided evolution of an indole 2-carboxylic acid fragment hit into a series of alpha-benzimidazolyl-substituted amino acids. Examples inhibited Pin1 activity with IC50 < 100 nM, but were inactive on cells. Replacement of the benzimidazole ring with a naphthyl group resulted in a 10-50-fold loss in ligand potency, but these examples downregulated biomarkers of Pin1 activity and blocked proliferation of PC3 cells. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.11.090

文献信息

• NOVEL ESTER COMPOUND AND PIN1 INHIBITOR, INFLAMMATORY DISEASE THERAPEUTIC, AND COLON CANCER THERAPEUTIC IN WHICH SAID ESTER COMPOUND IS USED
  申请人：Hiroshima University

  公开号：EP3549930A1

  公开（公告）日：2019-10-09

  An object of the present invention is to develop a therapeutic agent for an inflammatory disease such as an inflammatory bowel disease or NASH, which therapeutic agent shows less side effects and high effectiveness. The present invention provides a compound represented by Formula (I) or a salt thereof; and a Pin1 inhibitor, a pharmaceutical composition, a therapeutic agent or a prophylactic agent for an inflammatory disease, and a therapeutic agent or a prophylactic agent for colon cancer, containing the compound.

  本发明的目的是开发一种用于炎症性疾病（如炎症性肠病或 NASH）的治疗剂，该治疗剂副作用小且疗效显著。本发明提供了一种由式（I）代表的化合物或其盐；以及一种含有该化合物的 Pin1 抑制剂、一种药物组合物、一种炎症性疾病的治疗剂或预防剂，以及一种结肠癌的治疗剂或预防剂。
• NOVEL ANTHRANILIC ACID-BASED COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
  申请人：Hiroshima University

  公开号：EP3680232A1

  公开（公告）日：2020-07-15

  An object of the invention is to develop a group of new compounds with inhibitory activity against the function of Pinl as candidate compounds for drugs. The present invention provides compounds represented by the following Formula (I) or salts thereof, as well as Pin1 inhibitors, pharmaceutical compositions, therapeutic or prophylactic agents for inflammatory diseases, for cancer, and for obesity, which are prepared using the above compounds or salts thereof.

  本发明的目的是开发一组对 Pinl 功能具有抑制活性的新化合物，作为候选药物化合物。 本发明提供了由下式（I）代表的化合物或其盐类，以及利用上述化合物或其盐类制备的Pin1抑制剂、药物组合物、治疗或预防炎症性疾病、癌症和肥胖症的药物。
• NOVEL AMIDE COMPOUND, AND Pin1 INHIBITOR, THERAPEUTIC AGENT FOR INFLAMMATORY DISEASES AND THERAPEUTIC AGENT FOR CANCER THAT USE THE SAME
  申请人：Hiroshima University

  公开号：EP3680233A1

  公开（公告）日：2020-07-15

  An object of the invention is to develop a group of new compounds with inhibitory activity against the function of Pin1 as candidate compounds for drugs. The present invention provides compounds represented by the following Formula (I) or salts thereof, as well as Pin1 inhibitors, pharmaceutical compositions, therapeutic or prophylactic agents for inflammatory diseases, for cancer, and for obesity, which are each prepared using any of the above compounds or salts thereof.

  本发明的目的是开发一组对 Pin1 功能具有抑制活性的新化合物，作为候选药物化合物。 本发明提供了由下式（I）代表的化合物或其盐类，以及针对炎症性疾病、癌症和肥胖症的 Pin1 抑制剂、药物组合物、治疗剂或预防剂，它们都是使用上述化合物或其盐类制备的。
• THERAPEUTIC AGENT FOR FATTY LIVER DISEASES AND THERAPEUTIC AGENT FOR ADIPOSITY
  申请人：Hiroshima University

  公开号：EP3679930A1

  公开（公告）日：2020-07-15

  An object of the invention is to develop new therapeutic agents for fatty liver disease such as NASH or NAFLD. The present invention provides therapeutic or prophylactic agents for fatty liver disease, which comprise a compound represented by following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient. The present invention also provides therapeutic or prophylactic agents for obesity, which comprise a compound represented by following Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明的目的是开发治疗脂肪肝（如 NASH 或 NAFLD）的新药物。 本发明提供了治疗或预防脂肪肝的药物，其活性成分包括下式（I）所代表的化合物或其药学上可接受的盐。本发明还提供了治疗或预防肥胖症的制剂，其中包括下式(I)所代表的化合物或其药学上可接受的盐作为活性成分。
• Therapeutic agent for fatty liver diseases and therapeutic agent for adiposity
  申请人：Hiroshima University

  公开号：US11071738B2

  公开（公告）日：2021-07-27

  The purpose of the invention is to develop a novel therapeutic agent for fatty liver diseases such as NASH or NAFLD. The invention provides a therapeutic or prophylactic agent for fatty liver diseases that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof. The invention also provides a therapeutic or prophylactic agent for adiposity that comprises, as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof.

  本发明的目的是开发一种治疗脂肪肝（如 NASH 或 NAFLD）的新型治疗剂。 本发明提供了一种治疗或预防脂肪肝的药物，其活性成分包括由式（I）代表的化合物或其药学上可接受的盐。 本发明还提供了一种治疗或预防脂肪肝的药物，其活性成分包括式（I）代表的化合物或其药学上可接受的盐。